Operating Income (Loss) in USD of CNS Pharmaceuticals, Inc. from Q3 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
CNS Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2018 to Q3 2025.
  • CNS Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$3.25M, a 42.2% increase year-over-year.
  • CNS Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$13.2M, a 22.7% increase year-over-year.
  • CNS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$14.9M, a 21% increase from 2023.
  • CNS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$18.9M, a 23.6% decline from 2022.
  • CNS Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$15.3M, a 5.39% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

CNS Pharmaceuticals, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$13.2M -$3.25M +$2.38M +42.2% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-14
Q2 2025 -$15.6M -$2.41M +$119K +4.7% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-14
Q1 2025 -$15.7M -$4.34M -$793K -22.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-15
Q4 2024 -$14.9M -$3.2M +$2.18M +40.5% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-31
Q3 2024 -$17.1M -$5.63M -$1.1M -24.2% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-14
Q2 2024 -$16M -$2.53M +$1.5M +37.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-14
Q1 2024 -$17.5M -$3.54M +$1.38M +28% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-15
Q4 2023 -$18.9M -$5.38M -$245K -4.77% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-31
Q3 2023 -$18.6M -$4.53M -$1.11M -32.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$17.5M -$4.03M -$461K -12.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$17M -$4.93M -$1.78M -56.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$15.3M -$5.13M -$1.88M -57.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$13.4M -$3.42M +$394K +10.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$13.8M -$3.56M +$247K +6.48% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 -$14M -$3.15M +$460K +12.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$14.5M -$3.25M -$250K -8.33% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$14.2M -$3.81M -$1.8M -89.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$12.4M -$3.81M -$1.34M -54.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$11.1M -$3.61M -$1.64M -83.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$9.45M -$3M -$478K -18.9% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-03
Q3 2020 -$8.98M -$2.01M -$1.31M -188% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$7.66M -$2.47M -$2.06M -496% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$5.61M -$1.97M -$1.77M -909% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$3.83M -$2.52M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-12
Q3 2019 -$699K -$529K -311% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$415K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$195K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q3 2018 -$170K Jul 1, 2018 Sep 30, 2018 10-Q 2019-12-20

CNS Pharmaceuticals, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$14.9M +$3.96M +21% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-31
2023 -$18.9M -$3.6M -23.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-31
2022 -$15.3M -$781K -5.39% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
2021 -$14.5M -$5.03M -53.2% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$9.45M -$5.62M -147% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-03
2019 -$3.83M -$2.95M -335% Jan 1, 2019 Dec 31, 2019 10-K 2021-02-12
2018 -$882K Jan 1, 2018 Dec 31, 2018 10-K 2020-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.